19 September 2021 - Any lingering hope that Pfizer’s may finally get a regulatory approval for its nerve growth factor inhibitor tanezumab looks to have been dashed after the EMA’s human medicines committee rejected the medicine.

A positive recommendation was already looking like a long shot for after FDA advisors voted 15 to one against approval of the medicine in March. 

And while the EMA could go against the advice of the CHMP, it rarely does so.

Read Pharmaphorum article